Two Decades of Driving Treatment Development

Today's treatments are possible because friends like you support alopecia areata research and advocacy.





Primary convener of the alopecia areata research community, increasing scientific publications



2010

National Alopecia Areata Registry researchers identified eight genes that contribute to alopecia areata



2012

NAAF Treatment Development Program established, mapping a path to achieve treatments approved by the U.S. Food & Drug Administration (FDA)



2014

First physician published report of successful JAK inhibitor treatment



2017

NAAF community members begin participating in clinical trials for new treatments



2017

Patient focused drug development meeting with the FDA, landmark "Voice of the Patient" document published



2017

NAAF launches the Industry Partner Program (IPP) to foster collaboration and innovation as treatments are developed



2022

Milestone of the first FDA-approved treatment for adults



2023

Second FDA-approved treatment available for adults first treatment available for children ages 12 and older



2024

approval anticipated with more in the development pipeline

www.naaf.org/research

"Big thinking precedes great achievement."

- Wilferd Peterson

In June 2022, the U.S. Food and Drug Administration announced Olumiant™ as the first ever drug approved for the treatment for adults living with severe alopecia areata. In June 2023, a second drug, Litfulo™, was approved for the treatment of those 12+. These treatments are the culmination of BIG thinking combined with BIG action by the National Alopecia Areata Foundation (NAAF) community. It represents the successful outcome of two decades of focused effort by NAAF, the researchers NAAF funds and collaborates with, our industry partners, and our patient advocates--all made possible by NAAF donors.



